CardioFocus has announced that the first patients in France have been treated in the University Public Hospital of Nancy with the HeartLight endoscopic ablation system as part of a distribution partnership with MicroPort CRM France.
To date, more than 7,000 patients have been treated in the US, Europe and Japan, with the HeartLight System. Within Europe, France is one of the three largest markets for atrial fibrillation (AF) ablation technologies.
The HeartLight System is a catheter ablation technology for controlled and consistent pulmonary vein isolation (PVI), a gold standard treatment for AF. During PVI with the HeartLight System, laser energy is used to create lines of scar tissue to block the abnormal electrical pathways that cause AF.
In March, CardioFocus announced the European CE Mark approval and commercial launch of its third-generation technology, the HeartLight X3 system. This technology builds upon the features of the HeartLight system and offers a ‘Rapid’ mode which leverages a motor control system that enables high-speed, circumferential lesion creation under direct control of the physician resulting in consistently reduced procedure times.
“Electrophysiology is a strategic area of development for MicroPort CRM,” said Hervé Mayer, VP sales, MicroPort CRM France. “We are pleased to introduce this innovative technology to the French market. The first cases done by Dr Jean-Marc Sellal, have been very promising and we are very pleased to start a collaboration with the University Public Hospital of Nancy as a training and reference centre.”